Pegylated interferon 2a and ruxolitinib induce a high rate of oral complications among patients with myeloproliferative neoplasms.

EJHaem · 2020 · PMC9176112 · PMID 35847694

Europe PMC DOI

hedged sentence

0.0970

closest p · 1.9× alpha

0.0970

boldest claim

The sentences

a nonsignificant trendP = 0.097so close (0.05 < p ≤ 0.1)

Peg‐Ifn use was highly associated with gingival abscess (OR = 5.8, P = 0.004) and to a lesser degree to tooth loss (OR = 3.93, P = 0.053), whereas there was a nonsignificant trend toward association of ruxolitinib with tooth cracks (OR = 2.34, P = 0.097) (Table 1 ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.